Pembrolizumab in mycosis fungoides with PD-L1 structural variants
Sara Beygi, Sebastian Fernandez‐Pol, George E. Durán, Erica B. Wang, Henning Stehr, James L. Zehnder, Nirasha Ramchurren, Steven P. Fling, Martin A. Cheever, Wen‐Kai Weng, Youn H. Kim, Michael S. Khodadoust
Abstract
Key Points PD-L1 structural variants are recurrent in mycosis fungoides with large cell transformation. PD-L1 structural variants in relapsed/refractory mycosis fungoides should prompt consideration of treatment with PD-1 inhibitors.
Topics & Concepts
Mycosis fungoidesDermatologyMedicinePembrolizumabRefractory (planetary science)BiologyImmunologyLymphomaImmune systemImmunotherapyAstrobiologyCutaneous lymphoproliferative disorders researchCAR-T cell therapy researchFungal Infections and Studies